Advertisement

Topics

Swiss Biotech’s Immunotherapy for Brain Cancer gets Orphan Drug Designation

09:22 EDT 13 Sep 2017 | Labiotech.eu

The FDA will give special treatment to Vaximm’s oral T cell immunotherapy for glioma, which is particularly difficult to treat. Vaximm focuses on the development of oral T cell immunotherapies for cancers.  The FDA and European Commission have given Vaximm’s glioma candidate, VXM01, orphan designation, ...

This awesome article Swiss Biotech’s Immunotherapy for Brain Cancer gets Orphan Drug Designation appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: Swiss Biotech’s Immunotherapy for Brain Cancer gets Orphan Drug Designation

NEXT ARTICLE

More From BioPortfolio on "Swiss Biotech’s Immunotherapy for Brain Cancer gets Orphan Drug Designation"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...